Advertisement

Pharmaceutical Solvents for Pulmonary Drug Delivery

  • ERIK MOGALIAN
  • PAUL BRIAN MYRDAL
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VI)

Abstract

It must first be recognized that formulating compounds and delivering them as aerosols is complex. Not only does it involve the formulation of a stable solution or suspension in a medium (propellant) that is not as well characterized as other systems, but the resultant system is also subject to performance limitations. In order to efficiently reach the lung, the formulation must be atomized into particles having aerodynamic sizes between approximately 1 and 5 microns. Due to these particle size constraints, as well as inhalation toxicology concerns, the range of possible excipients to choose from during the formulation phase is substantially reduced. Additionally, limiting the concentration of excipients in a formulation is crucial for maintaining adequate aerosol performance. Thus, given the complexity of this relationship, formulating aerosols is a challenging endeavor.

Keywords

Beclomethasone Dipropionate Dose Inhaler Benzalkonium Chloride Mass Median Aerodynamic Diameter Chronic Obstructive Pulmonary Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benzalkonium Chloride Product Information. Sigma-Aldrich Inc., http://www. sigmaaldrich.com/sigma/product%20information%20sheet/b1383pis.pdf (accessed 5/2006)Google Scholar
  2. Bot AI, Tarara TE, Smith DJ, Bot SR, Woods CM, and Weers JG. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 2000; 17(3): 275–283.PubMedCrossRefGoogle Scholar
  3. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H, and Weers JG. Hollow Porous Particles in Metered Dose Inhalers. Pharm Res 2000; 17: 168–174.PubMedCrossRefGoogle Scholar
  4. FDA, 21 CFR (2), Use of Ozone-Depleting Substances; Essential-Use Determinations, Federal Register, 2002.Google Scholar
  5. Frinjlink HW, Eissens AC, Hefting NR, Poelstra K, Lerk CF, and Meijer DKF. The Effects of Parenterally Administered Cyclodextrins on Cholesterol Levels in the Rat. Pharm Res 1991; 8: 9–16.CrossRefGoogle Scholar
  6. Gupta A, Stein SW, and Myrdal PB. Balancing Ethanol Cosolvent Concentration with Product Performance in 134a-based Pressurized Metered Dose Inhalers. J Aerosol Med 2003; 16(2): 167–174.PubMedCrossRefGoogle Scholar
  7. Hoye WL, Mogalian E, and Myrdal PB. Effects of Extreme Temperatures on Drug Delivery of Albuterol Sulfate Hydrofluoroalkane Inhalation Aerosols. Am J Health-Sys Pharm 2005, 62: 2271–2277.CrossRefGoogle Scholar
  8. McDonald KJ and Martin GP. Transition to CFC-free Metered Dose Inhalers—into the New Millennium. Int J Pharm 2000; 201: 89–107.PubMedCrossRefGoogle Scholar
  9. Mogalian E and Myrdal PB. Application of USP Inlet Extensions to the TSI Impactor System 3306/3320 Using HFA 227 Based Solution Metered Dose Inhalers. Drug Devel Ind Pharm 2005; 31: 977–985.CrossRefGoogle Scholar
  10. Molina MJ and Rowland FS. Stratospheric Sink for Chlorofluoromethanes: Chlorine Atom-catalyzed Destruction of Ozone. Nature 1974; 249: 810–812.CrossRefGoogle Scholar
  11. Mumenthaler M, Hsu CC, and Pearlman R. Feasibility study on Spray-drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-type Plasminogen Activator. Pharm Res 1994; 11(1): 12–20.PubMedCrossRefGoogle Scholar
  12. Myrdal PB, Karlage KL, Stein SW, Brown BA, and Haynes A. Optimized Dose Delivery of the Peptide Cyclosporine Using Hydrofluoroalkane-Based Metered Dose Inhalers. J Pharm Sci 2004b; 93(4): 1054–1061.CrossRefGoogle Scholar
  13. Myrdal PB, Stein SW, Mogalian E, Hoye W, and Gupta A. Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: Solution Metered Dose Inhalers. Drug Devel Ind Pharm 2004a; 30(8): 859–868.CrossRefGoogle Scholar
  14. Pischtiak AH, Pittroff M, and Schwarze. Characteristics, supply and use of the ydrofluorocarbons HFA 227 and HFA 134a for medical aerosols in the past, present and future—Manufacturers perspectives. Drug Delivery to the Lungs XI. 2000; 1–5.Google Scholar
  15. Ridder KB, Davies-Cutting CJ, and Kellaway IW. Surfactant solubility and aggregate orientation in hydrofluoroalkanes. Int J Pharm 2005; 295: 57–65.PubMedCrossRefGoogle Scholar
  16. Smith IJ. The Challenge of Reformulation. J Aerosol Med 1995; 8(1): S19–S27.PubMedCrossRefGoogle Scholar
  17. Smyth HDC. The Influence of Formulation Variables on the Performance of Alternative Propellant-driven Metered Dose Inhalers. Adv Drug Deliv Rev 2003; 55: 807–828.PubMedCrossRefGoogle Scholar
  18. Solkane 227 pharma and Solkane 134a pharma Product Information. Solvay Fluor GmbH. www.solvay-fluor.com.Google Scholar
  19. Space Shuttle Program Petition for HCFC 141b Exemption Allowance. NASA http://www.nasa.gov/pdf/45331main/hcfc5/002.pdf (accessed 5/2006)Google Scholar
  20. Steckel H, Eskandar F, and Witthohn K. Effect of Excipients on the Stability and Aerosol Performance of Nebulized Aviscumine. J Aerosol Med 2003; 16(4): 417–432.PubMedCrossRefGoogle Scholar
  21. Stein SW and Myrdal PB. The Relative Influence of Atomization and Evaporation on Metered Dose Inhaler Drug Delivery Efficiency. Aerosol Science and Technology 2006; 40: 335–347.CrossRefGoogle Scholar
  22. Stein SW and Stefely JS. Reinventing Metered Dose Inhalers: From poorly Efficient CFC MDIs to Highly Efficient HFA MDIs. Drug Deliv Tech 2003; 3(1): 46–51.Google Scholar
  23. Taljanski W, Pierzynowski SG, Lundin DPD, Westrom BR, Eirefelt S, Podnesly J, Dahlback M, Siwinska-Golebiowska H, and Karlsson BW. Pulmonary Delivery of Intratracheally Instilled and Aerosolized Cyclosporine A to Young and Adult Rats. Drug Metabolism and Disposition 1997; 25(8): 917–920.PubMedGoogle Scholar
  24. Tiwari D, Goldman D, Malick WA, and Madan PL. Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a non-CFC Propellant. Pharm Dev Technol 1998; 3(2): 163–174.PubMedGoogle Scholar
  25. U.N. Handbook for the International Treaties for the Protection of the Ozone Layer, United Nations Environment Programme, Kenya, 1996.Google Scholar
  26. Vervaet C and Byron PR. Drug-Surfactant-Propellant Interactions in HFA Formulations. Int J Pharm 1999; 186: 13–30.PubMedCrossRefGoogle Scholar
  27. Wall DA, Marcello J, Pierdomenico D, and Farid A. Administration as Hydroxypropyl β-cyclodextrin Omplexes does not Slow Rates of Pulmonary Drug Absorption in Rat. STP Pharma Scienes 1994; 4(1): 63–68.Google Scholar
  28. Williams III RO and Hu C. Moisture Uptake and its Influence on Pressurized Metered-dose Inhalers. Pharm Devel Technol 2000; 5(2): 153–162.CrossRefGoogle Scholar
  29. Williams III RO and Liu J. Formulation of a Protein with Propellant HFA 134a for Aerosol Delivery. Eur J Pharm Sci 1998; 7: 137–144.CrossRefGoogle Scholar
  30. Williams III RO, Repka M, and Liu J. Influence of Propellant Composition on Drug Delivery from a Pressurized Metered-dose Inhaler. Drug Devel Ind Pharm 1998; 24(8): 763–770.CrossRefGoogle Scholar
  31. Zeng XM, Martin GP, and Marriott C. The Controlled Delivery of Drugs to the Lung. International Journal of Pharmaceutics 1995; 124: 149–164.CrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • ERIK MOGALIAN
    • 1
  • PAUL BRIAN MYRDAL
    • 1
  1. 1.College of PharmacyUniversity of ArizonaTucsonUSA

Personalised recommendations